Literature DB >> 6616962

Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

P S Friedmann, C Moss, S Shuster, J M Simpson.   

Abstract

We have developed quantitative methods which enable us to measure susceptibility to sensitization with dinitrochlorobenzene (DNBC) and the degree of responsiveness of groups, and to analyse factors affecting the afferent and efferent components of the response. Five groups of normal subjects (132 individuals) were sensitized with DNCB (1,000, 500, 250, 125 or 62.5 micrograms). One month later, each subject was challenged with 12.5, 6.25 and 3.125 micrograms of DNCB on standard patch test felts. After 48 h the reaction at each challenge site was graded clinically and measured as diameter of induration and increase in skinfold thickness. The proportion of subjects sensitized increased with sensitizing dose; 8% were sensitized by 62.5 and 100% were sensitized by 500 micrograms or more. The 50% sensitizing dose (ED50) was calculated as 116 micrograms. Increase in skinfold thickness proved the best method of assessing response and was linearly related to log challenge dose. There was also a linear relationship between degree of sensitivity and log sensitizing dose so that, on average, each time sensitizing dose was halved, the challenge dose required to produce the same response increased 1.5-fold. These methods can be used to measure sensitizability of a population, the degree of sensitivity and the expression of reactivity. The technique will allow quantitative study of factors altering the induction or expression of such reactivity in disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616962      PMCID: PMC1535656     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  6 in total

1.  IMMUNOLOGIC COMPETENCE OF PATIENTS WITH PSORIASIS RECEIVING CYTOTOXIC DRUG THERAPY.

Authors:  W L EPSTEIN; H I MAIBACH
Journal:  Arch Dermatol       Date:  1965-06

2.  A standrard method for DNCB sensitization testing in patients with neoplasms.

Authors:  E Bleumink; J P Nater; H Schraffordt Koops; T H The
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

3.  Attenuation of contact sensitization in man.

Authors:  E D Lowney
Journal:  J Invest Dermatol       Date:  1968-03       Impact factor: 8.551

4.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

5.  Endogenous cell-mediated immunity, blood transfusion, and outcome of renal transplantation.

Authors:  M A Watson; J D Briggs; A A Diamandopoulos; D N Hamilton; H M Dick
Journal:  Lancet       Date:  1979 Dec 22-29       Impact factor: 79.321

6.  Histamine weal formation and absorption in man.

Authors:  J Cook; S Shuster
Journal:  Br J Pharmacol       Date:  1980-08       Impact factor: 8.739

  6 in total
  16 in total

Review 1.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

Review 2.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 4.  Susceptibility to adverse drug reactions.

Authors:  Robin Ferner; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

5.  Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states.

Authors:  K Korver; E W Boeschoten; R T Krediet; G van Steenis; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Low-dose exposure to antigen induces sub-clinical sensitization.

Authors:  P S Friedmann; J Rees; S I White; J N Matthews
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Antigenic stimulation during ultraviolet therapy in man does not result in immunological tolerance.

Authors:  P S Friedmann; S I White; S Parker; C Moss; J N Matthews
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

8.  Susceptibility and amplification of sensitivity in contact dermatitis.

Authors:  C Moss; P S Friedmann; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

9.  Blood transfusion suppresses cutaneous cell-mediated immunity.

Authors:  J D Schot; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

10.  UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion.

Authors:  K D Cooper; L Oberhelman; T A Hamilton; O Baadsgaard; M Terhune; G LeVee; T Anderson; H Koren
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.